RE:My reason to buy CZO!Royal10 wrote: CZO is undervalued at 25 cents! I expect that Q1/24 will be financially positive following this news:
- From a business perspective, while 2023 was a challenging year due to a reorganization from one major customer in the United States, the company is pleased to announce that this customer has resumed ordering from Ceapro during Q1 2024, with a plus-20-metric-tonne order of avenanthramides.
That helps if the merger doesn't go through at this share price. The bottom line still might not be positive; however, given the costs of the pill trial, the costs of the proposed merger, and simultaneous scale-up of PGX at 5X and 10X; including with Natex. This company has many things on the go now.
If the merger goes through other factors will also be at play. At the current price, however, the merged company would still be trading below cash.
This was interesting. After announcing that the malted avenanthramide technology had been scaled to commercial volumes allowing CZO to produce from a single plant what four plants were needed to before CZO has now announced that it has sent a sample to a
major customer. CZO has also said in the past that it intended to sell directly to some clients in the future. Is CZO about to break into the food market; including with direct sales? Could avenanthramide not only have material health claims but control microbes like E coii in food? A major customer is interested. CZO's clinical trial may also be helping to establish potential health claims for avenanthramide.
News release:
- Enriched Oat Flourwith High Concentration of Avenanthramides:
- The first batch has been successfully produced. Samples have been sent to one major customer.
- The Company is assessing the potential of this product for preventive antimicrobial properties when used to produce oat based nutritional products.